ProCE Banner Activity

Advances in Cold Agglutinin Disease: Expert Answers to Your Most Pressing Questions

Clinical Thought

Read our responses to key questions from healthcare providers on the management of cold agglutinin disease using novel anti-complement C1–directed therapy and when to incorporate anti–B-cell targeted agents.

Released: December 22, 2023

Share

Faculty

Catherine M. Broome

Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

David Dingli

David Dingli, MD, PhD

Professor of Medicine
Division of Hematology
Mayo Clinic College of Science and Medicine
Rochester, Minnesota

Deva Sharma

Deva Sharma, MD, MS

Assistant Professor of Medicine
Divisions of Transfusion Medicine & Hematology-Oncology
Vanderbilt University Medical Center
Nashville, TN

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Sanofi.

Sanofi

Disclosure

Primary Author

Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

Catherine Broome, MD: consultant/advisor/speaker: Alexion, Argenx, Incyte, Sanofi; researcher: Alpine, Rigel, Star Therapeutics.

David Dingli, MD, PhD

Professor of Medicine
Division of Hematology
Mayo Clinic College of Science and Medicine
Rochester, Minnesota

David Dingli, MD, PhD: consultant/advisor/speaker: Alexion, Apellis Pharmaceuticals, AstraZeneca, Janssen, Novartis, Sanofi; data safety monitoring board: Sorrento Therapeutics.

Deva Sharma, MD, MS

Assistant Professor of Medicine
Divisions of Transfusion Medicine & Hematology-Oncology
Vanderbilt University Medical Center
Nashville, TN

Deva Sharma, MD, MS: consultant/advisor/speaker: Novo Nordisk, Sanofi, Terumo Blood and Cell Technologies.